IGNITE: Targeting Cyclin E1 altered high grade serous ovarian cancer (HGSC)

Dataset Name: A Phase II signal-seeking trial targeting recurrent high grade serous ovarian cancer (HGSC) with Cyclin E1 (CCNE1) over-expression with and without gene amplification – IGNITE
DOI: 10.58107/jzj9-rf14
Author(s): George Au-Yeung, Peter MacCallum Cancer Centre
Publisher: Australia New Zealand Gynaecological Oncology Group
Funding: AstraZeneca
Contributors: Australia New Zealand Gynaecological Oncology Group
Date made available: 2027
Dataset: Individual participant data
Patient sample size: 80
Dataset Description:
  • Data for 80 patients with recurrent high-grade serous carcinoma with Cyclin E1 (CCNE1) overexpression
  • Approximate time period of data collection 2020-2026
  • Clinical benefit rate at 18 weeks post-intervention commencement
  • Toxicity
  • Progression-free survival, overall survival
  • Best overall response (BOR)
  • Duration of response (DoR)
Requests for Data: Requests for data can be made through Health Data Australia
Link to main trial page: https://www.anzgog.org.au/research/trials/
Link to publication(s):
Subject:  (ANZCTR FOR)

Cancer therapy (excl. chemotherapy and radiation therapy)
Keywords: Cyclin E1, CCNE1, Ovarian Cancer, High Grade Serous, Adavosertib
Loading...